SILAC-based proteomic profiling of the human MDA-MB-231 metastatic breast cancer cell line in response to the two antitumoral lactoferrin isoforms: the secreted lactoferrin and the intracellular delta-lactoferrin.

<h4>Background</h4>Lactoferrins exhibit antitumoral activities either as a secretory lactoferrin or an intracellular delta-lactoferrin isoform. These activities involve processes such as regulation of the cell cycle and apoptosis. While lactoferrin has been shown to exert its function by...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Esthelle Hoedt, Karima Chaoui, Isabelle Huvent, Christophe Mariller, Bernard Monsarrat, Odile Burlet-Schiltz, Annick Pierce
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5f0eb9c57e654d92be40dada23785cd4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5f0eb9c57e654d92be40dada23785cd4
record_format	dspace
spelling	oai:doaj.org-article:5f0eb9c57e654d92be40dada23785cd42021-11-25T06:05:02ZSILAC-based proteomic profiling of the human MDA-MB-231 metastatic breast cancer cell line in response to the two antitumoral lactoferrin isoforms: the secreted lactoferrin and the intracellular delta-lactoferrin.1932-620310.1371/journal.pone.0104563https://doaj.org/article/5f0eb9c57e654d92be40dada23785cd42014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25116916/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Lactoferrins exhibit antitumoral activities either as a secretory lactoferrin or an intracellular delta-lactoferrin isoform. These activities involve processes such as regulation of the cell cycle and apoptosis. While lactoferrin has been shown to exert its function by activating different transduction pathways, delta-lactoferrin has been proven to act as a transcription factor. Like many tumor suppressors, these two proteins are under-expressed in several types of cancer, particularly in breast cancer.<h4>Methodology/principal findings</h4>In order to compare the differential effects of the re-introduction of lactoferrin isoforms in breast cancer cells we chose the cancerous mammary gland MDA-MB-231 cell line as a model. We produced a cell line stably expressing delta-lactoferrin. We also treated these cells with fresh purified human breast lactoferrin. We performed two quantitative proteomic studies in parallel using SILAC coupled to mass spectrometry in order to compare the effects of different doses of the two lactoferrin isoforms. The proteome of untreated, delta-lactoferrin expressing and human lactoferrin treated MDA-MB-231 cells were compared. Overall, around 5300 proteins were identified and quantified using the in-house developed MFPaQ software. Among these, expression was increased by 1.5-fold or more for around 300 proteins in delta-lactoferrin expressing cells and 190 proteins in lactoferrin treated cells. At the same time, about 200 and 40 proteins were found to be downregulated (0-0.7-fold) in response to delta-lactoferrin and lactoferrin, respectively.<h4>Conclusions/significance</h4>Re-introduction of delta-lactoferrin and lactoferrin expression in MDA-MB-231 mainly leads to modifications of protein profiles involved in processes such as proliferation, apoptosis, oxidative stress, the ubiquitin pathway, translation and mRNA quality control. Moreover, this study identified new target genes of delta-lactoferrin transcriptional activity such as SelH, GTF2F2 and UBE2E1.Esthelle HoedtKarima ChaouiIsabelle HuventChristophe MarillerBernard MonsarratOdile Burlet-SchiltzAnnick PiercePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 8, p e104563 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Esthelle Hoedt Karima Chaoui Isabelle Huvent Christophe Mariller Bernard Monsarrat Odile Burlet-Schiltz Annick Pierce SILAC-based proteomic profiling of the human MDA-MB-231 metastatic breast cancer cell line in response to the two antitumoral lactoferrin isoforms: the secreted lactoferrin and the intracellular delta-lactoferrin.
description	<h4>Background</h4>Lactoferrins exhibit antitumoral activities either as a secretory lactoferrin or an intracellular delta-lactoferrin isoform. These activities involve processes such as regulation of the cell cycle and apoptosis. While lactoferrin has been shown to exert its function by activating different transduction pathways, delta-lactoferrin has been proven to act as a transcription factor. Like many tumor suppressors, these two proteins are under-expressed in several types of cancer, particularly in breast cancer.<h4>Methodology/principal findings</h4>In order to compare the differential effects of the re-introduction of lactoferrin isoforms in breast cancer cells we chose the cancerous mammary gland MDA-MB-231 cell line as a model. We produced a cell line stably expressing delta-lactoferrin. We also treated these cells with fresh purified human breast lactoferrin. We performed two quantitative proteomic studies in parallel using SILAC coupled to mass spectrometry in order to compare the effects of different doses of the two lactoferrin isoforms. The proteome of untreated, delta-lactoferrin expressing and human lactoferrin treated MDA-MB-231 cells were compared. Overall, around 5300 proteins were identified and quantified using the in-house developed MFPaQ software. Among these, expression was increased by 1.5-fold or more for around 300 proteins in delta-lactoferrin expressing cells and 190 proteins in lactoferrin treated cells. At the same time, about 200 and 40 proteins were found to be downregulated (0-0.7-fold) in response to delta-lactoferrin and lactoferrin, respectively.<h4>Conclusions/significance</h4>Re-introduction of delta-lactoferrin and lactoferrin expression in MDA-MB-231 mainly leads to modifications of protein profiles involved in processes such as proliferation, apoptosis, oxidative stress, the ubiquitin pathway, translation and mRNA quality control. Moreover, this study identified new target genes of delta-lactoferrin transcriptional activity such as SelH, GTF2F2 and UBE2E1.
format	article
author	Esthelle Hoedt Karima Chaoui Isabelle Huvent Christophe Mariller Bernard Monsarrat Odile Burlet-Schiltz Annick Pierce
author_facet	Esthelle Hoedt Karima Chaoui Isabelle Huvent Christophe Mariller Bernard Monsarrat Odile Burlet-Schiltz Annick Pierce
author_sort	Esthelle Hoedt
title	SILAC-based proteomic profiling of the human MDA-MB-231 metastatic breast cancer cell line in response to the two antitumoral lactoferrin isoforms: the secreted lactoferrin and the intracellular delta-lactoferrin.
title_short	SILAC-based proteomic profiling of the human MDA-MB-231 metastatic breast cancer cell line in response to the two antitumoral lactoferrin isoforms: the secreted lactoferrin and the intracellular delta-lactoferrin.
title_full	SILAC-based proteomic profiling of the human MDA-MB-231 metastatic breast cancer cell line in response to the two antitumoral lactoferrin isoforms: the secreted lactoferrin and the intracellular delta-lactoferrin.
title_fullStr	SILAC-based proteomic profiling of the human MDA-MB-231 metastatic breast cancer cell line in response to the two antitumoral lactoferrin isoforms: the secreted lactoferrin and the intracellular delta-lactoferrin.
title_full_unstemmed	SILAC-based proteomic profiling of the human MDA-MB-231 metastatic breast cancer cell line in response to the two antitumoral lactoferrin isoforms: the secreted lactoferrin and the intracellular delta-lactoferrin.
title_sort	silac-based proteomic profiling of the human mda-mb-231 metastatic breast cancer cell line in response to the two antitumoral lactoferrin isoforms: the secreted lactoferrin and the intracellular delta-lactoferrin.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/5f0eb9c57e654d92be40dada23785cd4
work_keys_str_mv	AT esthellehoedt silacbasedproteomicprofilingofthehumanmdamb231metastaticbreastcancercelllineinresponsetothetwoantitumorallactoferrinisoformsthesecretedlactoferrinandtheintracellulardeltalactoferrin AT karimachaoui silacbasedproteomicprofilingofthehumanmdamb231metastaticbreastcancercelllineinresponsetothetwoantitumorallactoferrinisoformsthesecretedlactoferrinandtheintracellulardeltalactoferrin AT isabellehuvent silacbasedproteomicprofilingofthehumanmdamb231metastaticbreastcancercelllineinresponsetothetwoantitumorallactoferrinisoformsthesecretedlactoferrinandtheintracellulardeltalactoferrin AT christophemariller silacbasedproteomicprofilingofthehumanmdamb231metastaticbreastcancercelllineinresponsetothetwoantitumorallactoferrinisoformsthesecretedlactoferrinandtheintracellulardeltalactoferrin AT bernardmonsarrat silacbasedproteomicprofilingofthehumanmdamb231metastaticbreastcancercelllineinresponsetothetwoantitumorallactoferrinisoformsthesecretedlactoferrinandtheintracellulardeltalactoferrin AT odileburletschiltz silacbasedproteomicprofilingofthehumanmdamb231metastaticbreastcancercelllineinresponsetothetwoantitumorallactoferrinisoformsthesecretedlactoferrinandtheintracellulardeltalactoferrin AT annickpierce silacbasedproteomicprofilingofthehumanmdamb231metastaticbreastcancercelllineinresponsetothetwoantitumorallactoferrinisoformsthesecretedlactoferrinandtheintracellulardeltalactoferrin
_version_	1718414224988831744

SILAC-based proteomic profiling of the human MDA-MB-231 metastatic breast cancer cell line in response to the two antitumoral lactoferrin isoforms: the secreted lactoferrin and the intracellular delta-lactoferrin.

Ejemplares similares